

HMGB1 in neurodegeneration, neuroinflammation.

NEURODEGENERATION / NEUROTRANSMITTER

Manufactured by

IBL International GmbH
Flughafenstrasse 52a
D-22335 Hamburg
Germany

Phone: +49 (0)40-53 28 91-0
Fax: +49 (0)40-53 28 91-11
Email: IBL@Tecan.com
www.tecan.com/immunoassays

IBL
INTERNATIONAL
Empowered with Tecan

Australia +61 3 9647 4100 **Austria** +43 62 46 89 33 **Belgium** +32 15 42 13 19 **China** +86 21 220 63 206 **Denmark** +45 70 23 44 50 **France** +33 4 72 76 04 80
Germany +49 6134 1814 30 **Italy** +39 02 92 44 790 **Japan** +81 44 556 73 11 **Netherlands** +31 18 34 48 17 4 **Singapore** +65 644 41 886 **Spain** +34 93 490 01 74
Sweden +46 31 75 44 000 **Switzerland** +41 44 922 89 22 **UK** +44 118 9300 300 **USA** +1 919 361 5200 **Other countries** +43 62 46 89 33

Tecan Group Ltd. makes every effort to include accurate and up-to-date information; however, it is possible that omissions or errors might have occurred. Tecan Group Ltd. cannot, therefore, make any representations or warranties, expressed or implied, as to the accuracy or completeness of the information provided. Changes can be made at any time without notice. All mentioned trademarks are protected by law. In general, the trademarks and designs referenced herein are trademarks, or registered trademarks, of Tecan Group Ltd., Maennedorf, Switzerland. A complete list may be found at www.tecan.com/trademarks. Product names and company names that are not contained in the list but are noted herein may be the trademarks of their respective owners. For technical details and detailed procedures of the specifications provided please contact your Tecan representative. This may contain reference to applications and products which are not available in all markets. Please check with your local sales representative.

© 2016 Tecan Trading AG, Switzerland, all rights reserved. For disclaimer and trademarks please visit www.tecan.com

HMGB1 Neuro. EN 2016 V01

Distributed by Abacus dx

1800 ABACUS (AUS) 0800 222 170 (NZ) | info@abacusdx.com | www.abacusdx.com

abacus dx

HMGB1

in CNS-related pathologies.


More recent research shows that HMGB1 plays a major role in CNS-related pathologies. The involvement of the innate immune system and thus HMGB1 in the development of these pathologies has not been studied in depth so far.

Only more recent research in the field of neurodegeneration has indicated that the role of the immune system in the development of neurodegenerative and neuroinflammatory processes hasn't truly been examined. HMGB1 has been shown to be an important mediator of the immune system.

Early research in 2003 showed that HMGB1 seems to regulate Amyloid-beta homeostasis and that HMGB1 stabilizes Amyloid-beta oligomers¹. In later publications it was further shown that HMGB1 seems to inhibit microglial clearance of Amyloid-beta^{2,3}.

Since then the role of HMGB1 has been studied in many more CNS-related pathologies, such as HIV-Associated Neurodegenerative Disorders^{4,5}, Parkinson's disease⁶, multiple sclerosis⁷, Guillain-Barré Syndrome⁸, Traumatic brain Injury (TBI)⁹, Acute Hydrocephalus¹⁰ and often their respective animal models^{11,12}.

IBL International at the center of HMGB1 research Through its collaboration with HMGB1 experts from academia and commercial partners, IBL International is at the forefront of new developments. We at IBL International offer the most complete range of products - including a highly sensitive ELISA for the quantitative measurement of HMGB1 - which have been widely used and are cited in many publications.



Amyloidogenic and amyloid binding motif of HMGB1 (Kallijärvi J. et al. Biochemistry. 2001; 40(34):10032-7.)

- Takata K. et al. Role of high mobility group protein-1 (HMG1) in amyloid- β homeostasis. *Biochem Biophys Res Commun.* 2003;301(3):699-703.
- Takata K. et al. High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. *J Neurosci Res.* 2004;78(6):880-91.
- Takata K. et al. Microglial Amyloid- β -1-40 Phagocytosis Dysfunction Is Caused by High-Mobility Group Box Protein-1: Implications for the Pathological Progression of Alzheimer's Disease. *Int J Alzheimers Dis.* 2012;2012:685739.
- Saïdi H. et al. HMGB1-dependent triggering of HIV-1 replication and persistence in dendritic cells as a consequence of NK-DC cross-talk. *PLoS One.* 2008;3(10):e3601.
- Melki MT. et al. Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk--a pivotal role of HMGB1. *PLoS Pathog.* 2010 Apr 15;6(4):e1000862.
- Santoro M. et al. In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin. *Neurobiol Dis.* 2016;91:59-68.
- Wang H. et al. Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis. *Neuroimmunomodulation.* 2013;20(2):113-118.
- Zhang DQ. et al. Reduced soluble RAGE is associated with disease severity of axonal Guillain-Barré syndrome. *Sci Rep.* 2016 Feb 23;6:21890

9-37 If you wish to receive a complete list of the referenced articles, please contact us at ibl@tecan.com

HMGB PRODUCTS

Immunoassay	Catalog#	Determ.	Assay range	Incubation time	Sample type
HMGB1 ELISA	ST51011	96 well	2.5 - 80 ng/mL or 0.313 - 10 ng/mL	1st: 37 °C, 18 h 2nd: RT, 2 h 3rd: RT, 30 min	Serum ¹³ , plasma ¹⁴ , BALF ¹⁵ , CSF ¹⁶ , urine ¹⁷ , cell culture supernatant ¹⁸ and tissue extracts ¹⁹ All mammals ²⁰⁻²³

For Research use only

Antibodies*	Catalog#	Quantity	Intended use
Anti-HMGB1 Rabbit IgG PoAb	ST326052219	50 μ g	WB (1-2 μ g/mL), IHC ²⁴ , immunofluorescence ²⁵ and immunoprecipitation ²⁶
Anti-HMGB1 Chicken IgY PoAb	ST326052226	50 μ g	WB ²⁷ (1-2 μ g/mL)
Anti-HMGB1 Chicken IgY Neutralising PoAb	ST326052233	1 mg	WB and neutralization experiments ²⁸⁻³¹ (2 mg/kg/mouse)
Anti-HMGB1,2 Mouse IgG1 MoAb	ST326052240	50 μ g	WB (1-2 μ g/mL)
Anti-HMGB1 [DPH1.1] Mouse IgG1 MoAb	REHM901	50 μ g	WB ³² (1 μ g/mL), immunofluorescence ³² , IHC, blocking experiments in cell migration assay ³² and blocking recruitment of inflammatory cells to sites of necrosis and infection in vitro and in vivo (220 μ g/mouse) ³²
	REHM902	250 μ g	
	REHM903	1 mg	

Protein isoforms and related proteins*	Catalog#	Quantity	Intended use
Fully reduced HMGB1, LPS-free	REHM114	500 μ g	To study HMGB1 cell migratory effects in vitro ³³ and in vivo
	REHM115	100 μ g	
	REHM116	50 μ g	
Disulfide HMGB1, LPS-free	REHM120	500 μ g	To study HMGB1 induced cytokine effects in proinflammatory processes ³⁵
	REHM121	100 μ g	
	REHM122	50 μ g	
BoxA from HMGB1, LPS-free	REHM012	100 μ g	To study HMGB1-RAGE interaction by using BoxA as an antagonist for HMGB1 ^{33,34}
	REHM013	500 μ g	
	REHM014	2 mg	
BoxB from HMGB1, LPS-free	REHM052	100 μ g	To study HMGB1 induced cytokine activity by measuring BoxB as a read out ³⁶
	REHM051	250 μ g	
	REHM050	1 mg	
HMGB2, LPS-free	REHM151	500 μ g	To study HMGB2 induced fibroblast migration ³⁷
	REHM152	100 μ g	
	REHM153	50 μ g	

* Distributed by IBL International